Status:
COMPLETED
Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
Lead Sponsor:
Karo Bio AB
Conditions:
Primary Hypercholesterolemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue. Eprotirome has in a clinical 2-...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- clinical diagnosis of hypercholesterolemia
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT00776321
Start Date
September 1 2006
End Date
October 1 2007
Last Update
October 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jens Kristensen
Huddinge, Sweden